Are peptides safe?

"Are peptides safe" is really two questions wearing one coat. One is about the molecules themselves, which range from decades-proven medicines to compounds tested only in mice. The other is about the supply chain you are buying from, which is where most documented harm occurs. You have to separate them or the answer makes no sense.

The molecule question: FDA-approved vs. everything else

Some peptides are among the most extensively studied drugs in medicine. Insulin is a peptide. So is semaglutide, the active compound behind Ozempic and Wegovy, which completed large randomized human trials before approval.¹ For these, "safe" means what it means for any prescription drug: known side effects, known dosing ranges, known interactions, taken under medical supervision.

According to Stanford Medicine, the FDA has approved roughly 100 different peptide therapeutics since injectable insulin first became available — for conditions ranging from diabetes to multiple sclerosis to growth hormone deficiency.⁴ That is a large and well-studied class of medicines. The approval process required human safety data and defined dosing before any of them reached a patient.

Many popular wellness peptides are a completely different story. Compounds like BPC-157, TB-500, and various growth-hormone-releasing peptides have early animal research, but human safety data is thin or absent. "Promising in a rat study" is not the same as "shown safe in people," and honest sources will not pretend otherwise.

Category	Human safety evidence	Regulatory status
FDA-approved peptide drugs (insulin, semaglutide, tesamorelin)	Robust. Large human trials. Known risk profile.	Approved. Requires prescription.
Wellness peptides not yet through trials (BPC-157, TB-500, GHK-Cu)	Minimal. Mostly animal studies. Human safety data very limited.	Not approved. Banned from most compounding.
"Research use only" vials from online vendors	Unknown. No purity, sterility, or dose verification required.	Legal to sell for lab research only. Not for human use.

What the FDA has approved — and removed from pharmacies

The gap between "FDA-approved peptide" and "wellness peptide" is not a matter of paperwork. It reflects a fundamental difference in how much is actually known about what happens when these molecules enter a human body.

In late 2023, the FDA moved 19 widely used wellness peptides — including BPC-157, TB-500, and several growth-hormone-releasing compounds — off the list of substances that licensed compounding pharmacies could legally prepare. The FDA's own language for certain of these substances cites "risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities" and notes "FDA has identified no, or only limited, safety-related information for the proposed routes of administration."⁵

For GHRP-2, the FDA's Category 2 substances page states it is "aware of reports of serious adverse events in patients who received GHRP-2, including increased insulin requirement, death of critically ill study subjects, infection and pancreatitis." For Ipamorelin, the agency notes "a study published in literature identified serious adverse events including death when ipamorelin was administered intravenously."⁵ Causality was not established in either case, but these are the kinds of signals that triggered the removal from compounding.

In July 2026, an FDA advisory committee voted 8 to 6 (with one abstention) to recommend that BPC-157, TB-500, and several other peptides be added back to the compounding list — a narrow margin that reflects how genuinely unsettled the science remains. The committee did not vote on efficacy. It voted only on whether there was enough safety data to allow supervised compounding. Half the voting members have financial ties to companies that offer peptide therapies.

The supply-chain question: this is where the real risk lives

A large share of peptides sold online carry a "research use only" label. That label means the product is legal to sell for laboratory research but is not intended, tested, or regulated for human consumption. There is no requirement that the vial contains what the label says, at the purity it says, free of contaminants.

The American Medical Association has specifically warned patients about self-injecting peptides bought this way, citing contamination and dosing risks. The AMA notes that newer, unapproved peptides are increasingly being sold at wellness spas and online through the gray market, where products are manufactured with no FDA oversight and people inject them with no lab testing and no medical supervision.

Researchers and physicians who study this area describe the practical consequence of buying peptides online as a fundamental verification problem. Dr. Jack Spittler, an orthopedic surgeon and associate professor at the University of Colorado who also serves as a team physician for the Denver Nuggets, has described the issue directly: "When you're buying peptides online, they have no real concept of the purity of what you're getting, or even if it's what it says it is at all. There could be heavy metals, there could be other medications, there could be a lot of different things that you're putting in your body that could actually be very unhealthy."

What purity testing of gray-market peptides has actually found

This is not hypothetical. Published analytical chemistry research examining peptides sourced from suspected illegal internet pharmacies has found purity as low as 5 percent in cysteine-containing peptides — meaning up to 95 percent of the contents were impurities, not the labeled compound. Multiple samples in that research contained arsenic at concentrations up to ten times the International Council for Harmonisation toxicity limit for injectable drugs. One sample was contaminated with lead.

Critically, there is no mandatory federal verification requirement standing between a gray-market vendor and the buyer. No federal body checks purity, potency, or sterility of a vial sold as "research use only" before it ships. The FDA has issued warning letters to bulk peptide producers citing sterility violations and placed some firms on import alert, but the market is large and enforcement is reactive rather than preventive.⁵

This is what physicians mean when they say the real risk is the supply chain, not necessarily the molecule. An impure, contaminated vial causes harm regardless of what is printed on the label.

What the side effect evidence actually shows

Side effects depend heavily on the specific peptide and the quality of what is being injected. For well-characterized, FDA-approved peptides the picture is relatively clear: in the landmark STEP 1 trial of semaglutide (1,961 participants, 68 weeks), 86.4 percent of participants achieved at least 5 percent weight loss, but 4.5 percent of the semaglutide group discontinued due to gastrointestinal side effects — compared to 0.8 percent on placebo.³ Nausea and diarrhea were the most common events; most were transient and mild to moderate. That is what "known side effects under medical supervision" looks like: documented, monitored, and weighed against a clear benefit.

For unapproved wellness peptides, the picture is far less clear. As of the FDA's July 2026 advisory committee briefing, there were only 3 documented adverse event reports from BPC-157 injections in the agency's records. One involved nine days of redness and swelling at the injection site. The paucity of reports does not mean the compound is safe — it reflects the fact that most use occurs informally and is never tracked.

The only published human IV safety study of BPC-157 enrolled 2 participants — a 58-year-old and a 68-year-old — and found no measurable changes in cardiac, liver, kidney, or thyroid markers at the doses tested.⁶ That is the entirety of published human IV safety data for one of the most widely injected wellness peptides. What the compound does in larger groups, over longer timeframes, or in people with underlying conditions is not known.

Harvard Health Publishing notes that some injectable peptides "could trigger abnormal immune system responses, leading to allergic reactions (including severe ones like anaphylaxis) or autoimmune issues in some people" — a risk category that no standard side-effect list captures.²

"As a clinician, I do not recommend injecting yourself with peptides."

— Dr. Pieter Cohen, Associate Professor of Medicine, Harvard Medical School, in Harvard Health Publishing

What researchers who work with these compounds say

Some of the clearest warnings about self-administering research-grade peptides come from scientists who use these compounds professionally in laboratory settings — people who understand both the potential and the current limits of the evidence.

"First of all, there could be all sorts of contaminants in that solution that you're injecting into yourself. Second, there's no data about whether these peptides actually do anything or their toxicity. You just don't know what you're putting in your body."

— Dr. Jonathan Long, Associate Professor of Pathology, Stanford School of Medicine

"I work with these experimental peptides myself. I know how potent some of them can be. I would not be comfortable taking any research-grade peptides."

— Dr. Katrin Svensson, Associate Professor of Pathology, Stanford School of Medicine

Mansoor Amiji, Professor of Pharmaceutical Sciences and Chemical Engineering at Northeastern University, has put the gap between hype and evidence plainly: "Except for GLP-1 agonists by Eli Lilly and Novo, and other FDA-approved peptides, there are no preclinical or clinical studies showing safety and effectiveness of these 'hyped' peptides."

Evidence levels for commonly discussed peptides

Not all peptides sit in the same place on the evidence spectrum. This table reflects the current state of human safety data — not effectiveness, just how much is actually known about what these compounds do in people.

Peptide	Human safety data	FDA status	Key gap
Insulin	100+ years of clinical use, extensive data	Approved	Well characterized. Requires monitoring.
Semaglutide (GLP-1)	Large phase III trials including 1,961 participants in STEP 1	Approved (T2D, obesity)	Long-term cardiovascular data still accumulating
Tesamorelin	Phase III trials completed	Approved (HIV-associated lipodystrophy)	Data limited outside approved indication
BPC-157	2 humans in one pilot study (2025)	Not approved; removed from compounding	Dose, long-term effects, interactions all unknown
TB-500 (Thymosin β-4 fragment)	No published human safety trials	Not approved; removed from compounding	No human data at all
CJC-1295 / Ipamorelin	No published human safety trials; Ipamorelin IV associated with death in animals	Not approved; Ipamorelin removed from compounding	FDA flagged serious adverse events for Ipamorelin
GHK-Cu (injectable)	No published human safety trials for injection	Not approved; removed from compounding	Injectable safety entirely unknown

How widely are peptides being used right now?

The wellness peptide market has grown dramatically and faster than the evidence base supporting it. U.S. peptide-related online searches hit an estimated 10.1 million per month in early 2026 — roughly five times the volume seen in 2020 — according to wellness industry tracking data. The growth is outpacing any comparable expansion in human clinical research.

GLP-1 medications, the one peptide category with a robust FDA-approval track record, have seen the most visible uptake: a 2024 CDC National Health Interview Survey found that 26.5 percent of U.S. adults with diagnosed diabetes reported using GLP-1 injectables, and spending on GLP-1 medications increased by more than 500 percent from 2018 to 2023.⁷ The prescription data on approved GLP-1s is comprehensive precisely because these drugs went through the regulatory process — adverse events get reported, dosing gets studied, interactions get flagged.

The wellness peptides being injected outside that system generate no equivalent data. There is no national registry of who is using BPC-157 or TB-500, at what doses, for how long, or with what outcomes. The absence of documented harm is not the same as an established safety record. It largely reflects the absence of any system for tracking harm in the first place.

The safer path, if you are going to explore peptides

• Go through a licensed physician or a legitimate telehealth clinic that prescribes through a licensed compounding pharmacy, requires bloodwork, and monitors you over time. That oversight is the entire point — it is what changes the risk profile.
• Ask specifically about the human evidence for your peptide and your goal. If the answer is "lots of animal research," that is not the same as human safety data, and you deserve to know the difference.
• Treat any online seller that ships injectable peptides with no prescription, no required physician contact, and no pharmacy label as an unregulated chemical supplier — because that is the regulatory category it occupies.
• Ask your provider which legal and regulatory status applies to what they are prescribing. The answer tells you a great deal about how much is actually known.

We walk through exactly how supervised access works, and how to identify a legitimate clinic versus a gray-market storefront, on our safest way to try peptides page. Understanding what peptides are and how they differ from one another is also useful context before evaluating any specific option.

Frequently asked questions

Are BPC-157 or TB-500 safe to self-inject?

The honest answer is that the evidence base for saying so does not exist. The only published human IV safety study of BPC-157 enrolled 2 people, for one trial. TB-500 has no published human trials at all. Neither compound is FDA-approved for human use. The FDA removed both from most compounding pharmacy lists in 2023. Whether these compounds could, with proper study, prove safe and useful is a separate question from whether they are established as safe now. They are not.

Is semaglutide (Ozempic, Wegovy) a peptide? Is it safe?

Yes, semaglutide is a GLP-1 receptor agonist — a modified peptide. It went through large randomized controlled trials involving thousands of participants before FDA approval. The STEP 1 trial enrolled 1,961 adults and ran for 68 weeks; side effects were documented, monitored, and weighed against measurable outcomes. Semaglutide under medical supervision has a well-characterized risk profile. Compounded semaglutide from unverified sources — which became widespread when branded versions faced shortages — does not carry the same assurance of purity and dose accuracy.

What does "research use only" actually mean?

"Research use only" (RUO) is a legal label that means a product is sold for in vitro or laboratory animal research, not for human administration. There is no federal requirement that an RUO product meet pharmaceutical-grade purity or sterility standards. The label exists to legally classify the product — not to imply safety, efficacy, or quality for any other purpose. When a person injects an RUO peptide, they are using a chemical compound that was never intended, tested, or regulated for that use.

Do doctors ever prescribe the wellness peptides?

Some physicians at longevity and functional medicine clinics prescribe peptides like BPC-157 and CJC-1295/Ipamorelin through compounding pharmacies, a practice that existed before the 2023 FDA restrictions. Whether and how that changes following the July 2026 advisory committee recommendation remains unsettled. A prescription through a licensed pharmacy does meaningfully improve the quality and sterility assurance compared to a gray-market vial — but it does not create evidence of efficacy or supply the long-term safety data that does not yet exist.